Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viewpoint: limiting prostate cancer screening.

Richard M Hoffman1

  • 1New Mexico Veterans Affairs Health Care System and the Cancer Research and Treatment Center, University of New Mexico School of Medicine, Albuquerque, New Mexico 87108, USA. rhoffman@unm.edu

Annals of Internal Medicine
|March 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Applying artificial intelligence to ensure high quality and equitable lung cancer screening.

Translational lung cancer research·2026
Same author

Colorectal cancer screening: An update to the American Cancer Society guideline, 2026.

CA: a cancer journal for clinicians·2026
Same author

A DNA Methylation-based algorithm Improves Lung Cancer risk prediction in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Significant Incidental Findings in the National Lung Screening Trial and Diagnosis of Extrapulmonary Cancer.

JAMA network open·2026
Same author

Patient-reported Psychological and Prostate Cancer-specific Functional Outcomes Among Men With Low-risk Prostate Cancer Two Years After Diagnosis: The PREPARE Prospective Cohort Study.

Urology·2026
Same author

Can We Really Do Better? Why PSA Cutpoints Are Still Useful for Primary Care Clinicians.

Journal of general internal medicine·2026

Prostate cancer screening using prostate-specific antigen (PSA) shows unconvincing efficacy. Current evidence does not support expanding screening for average-risk men younger than 50 or older than 75, nor using PSA levels below 4.0 ng/mL for biopsy referrals.

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • Prostate cancer screening guidelines differ among professional organizations, creating controversy.
  • The efficacy of prostate-specific antigen (PSA) screening remains a subject of debate.
  • Key issues include PSA criteria for biopsy, optimal screening initiation age, and cessation age.

Purpose of the Study:

  • To critically evaluate the evidence for prostate cancer screening efficacy, particularly PSA-based screening.
  • To provide recommendations on PSA screening criteria, age to start, and age to stop screening.
  • To address the controversy surrounding prostate cancer screening guidelines.

Main Methods:

  • Review of scientific evidence published since 2000 concerning prostate cancer screening.

Related Experiment Videos

  • Analysis of data related to prostate-specific antigen (PSA) levels and biopsy recommendations.
  • Evaluation of age-related data for initiating and terminating screening protocols.

    • Main Results:

    • Evidence supporting the efficacy of PSA screening published since 2000 is considered unconvincing.
    • Data do not support expanding screening to average-risk men younger than 50 or older than 75 years.
    • A PSA threshold below 4.0 ng/mL is not recommended for triggering prostate biopsy referrals.

    Conclusions:

    • Current evidence does not convincingly support widespread PSA-based prostate cancer screening.
    • Recommendations are made to limit screening to specific age ranges (50-75 years for average-risk men) and PSA thresholds (not below 4.0 ng/mL).
    • Further research and re-evaluation of screening protocols are warranted given the controversial nature and evolving evidence.